Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xylia Q. Peters
Observed name:
Xylia Perters
Institution:
University of KwaZulu-Natal
Observed institution:
University of KwaZulu-Natal
ORCID:
0000-0002-4872-4097
Observed ORCID:
0000-0002-4872-4097
OpenAlex ID:
A5012079998
Potential of nanocarrier-mediated delivery of vancomycin for MRSA infections
2025
·
Vincent O. Nyandoro
, Eman A. Ismail
, et al.
·
Expert Opinion on Drug Delivery
·
27
Engineering dynamic covalent bond-based nanosystems for delivery of antimicrobials against bacterial infections
2024
·
Abdelrahman Tageldin
, Calvin A. Omolo
, et al.
·
Journal of Controlled Release
·
21
Antimicrobial peptide-fucoidan nanoplexes: A novel multifunctional biomimetic nanocarrier for enhanced vancomycin delivery against bacterial infections and sepsis
2025
·
Mohammed A. Gafar
, Calvin A. Omolo
, et al.
·
International Journal of Pharmaceutics
·
14
Multifunctional Dual Enzyme-Responsive Nanostructured Lipid Carriers for Targeting and Enhancing the Treatment of Bacterial Infections
2024
·
Kerisha Chetty
, Xylia Q. Peters
, et al.
·
ACS Applied Bio Materials
·
9
Unravelling the Structural Mechanism of Action of 5-methyl-5-[4-(4-oxo-3H-quinazolin-2-yl)phenyl]imidazolidine-2,4-dione in Dual-Targeting Tankyrase 1 and 2: A Novel Avenue in Cancer Therapy
2022
·
Xylia Q. Peters
, Clement Agoni
, et al.
·
Cell Biochemistry and Biophysics
·
8
Zoning in on Tankyrases: A Brief Review on the Past, Present and Prospective Studies
2019
·
Xylia Q. Peters
, Thembeka H. Malinga
, et al.
·
Anti-Cancer Agents in Medicinal Chemistry
·
6
Therapeutic Path to Triple Knockout: Investigating the Pan-inhibitory Mechanisms of AKT, CDK9, and TNKS2 by a Novel 2-phenylquinazolinone Derivative in Cancer Therapy- An In-silico Investigation Therapy
2023
·
Xylia Q. Peters
, Ghazi Elamin
, et al.
·
Current Pharmaceutical Biotechnology
·
5
Pharmacophore-based Identification of Potential Mutant Isocitrate Dehydrogenases I/2 Inhibitors: An Explorative Avenue in Cancer Drug Design
2022
·
Mahmoud E.S. Soliman
, Preantha Poonan
, et al.
·
Anti-Cancer Agents in Medicinal Chemistry
·
5
Enhancing activity and overcoming ciprofloxacin resistance via multifunctional nanostructured lipid carriers
2025
·
Sbongumusa Dlamini
, Calvin A. Omolo
, et al.
·
Journal of Drug Delivery Science and Technology
·
4
Paving the Way for NLRP3 Inflammasome Inactivation Using ADAM10 and Alpha-Hemolysin: An In Silico Investigation
2025
·
Xylia Q. Peters
, Calvin A. Omolo
, et al.
·
ACS Omega
·
3
Exploring the Effects of Chirality of 5-methyl-5-[4-(4-oxo-3H-quinazolin-2- yl)phenyl]imidazolidine-2,4-dione and its Derivatives on the Oncological Target Tankyrase 2. Atomistic Insights
2023
·
Xylia Q. Peters
, Preantha Poonan
, et al.
·
Current Pharmaceutical Biotechnology
·
3
Targeting the ADAM10-Alpha Hemolysin Axis Using Ascorbyl Stearate as a Potential Therapy in S. aureus Infections: In Silico and MST Studies
2025
·
Vincent O. Nyandoro
, Xylia Q. Peters
, et al.
·
ACS Omega
·
2
Targeting resistance via a redox-sensitive AMP-Based delivery system that broadens vancomycin activity
2026
·
Sania Z.F. Kassam
, Eman A. Ismail
, et al.
·
Journal of Drug Delivery Science and Technology
Show more works
View as search
Works count:
13
Citation count:
107
H-index:
6
I10-index:
3
Year
Topic
Type